Understand · Treat · Recover
Blood Cancer Investigations Explained
Tests answer different questions: what the disease is, where it is, which treatment may work and how well treatment has worked.
For patients and families. This education does not replace an individual treatment plan. Do not start, stop or change medicines without the treating team.
Chapter 13 of 20 · F · Diagnosis and testing
CBC, differential and blood smear
A complete blood count measures hemoglobin, white cells and platelets. The differential separates white-cell types; the absolute neutrophil count helps assess infection risk. A smear allows a laboratory specialist to inspect cell appearance. Abnormal counts are clues, not a complete cancer diagnosis. Normal counts do not exclude all lymphomas or plasma-cell disorders. Trends and symptoms matter, and reference ranges vary by laboratory and age.
Marrow aspiration and biopsy
An aspirate takes a liquid marrow sample, usually from the back of the hip bone. A trephine biopsy takes a small core showing the marrow structure. Local anesthetic is used; sedation may be discussed, particularly for children. A “dry tap” means little liquid was obtained, not that the marrow is normal or that the procedure necessarily failed. The core and other samples can still be informative. Follow the centre’s instructions about anticoagulants, dressings and when to report bleeding, fever or worsening pain.
Cell identity versus genetic instructions
| Test | Main question | Important limitation |
|---|---|---|
| Flow cytometry | Which cell populations and marker patterns are present? | Requires suitable cells; sample and marker panel matter |
| IHC | Which proteins are expressed in tissue, and where? | Protein staining does not establish every gene alteration |
| Karyotype / cytogenetics | Are there larger chromosome changes? | May require dividing cells |
| FISH | Is a specific chromosome or gene change present? | Only examines the selected targets |
| Molecular testing / NGS | Are specified gene changes present? | Coverage and sensitivity vary; a negative panel is not “no mutations” |
Peripheral blood and marrow can yield different information. Reports from different laboratories or sample types must not be treated as identical measurements. A variant of uncertain significance is not automatically a treatment target.
Imaging and tissue
PET-CT assesses metabolically active sites in many lymphomas; CT and MRI answer other anatomical questions. Infection can cause PET uptake, and some cancers are less PET-avid. For myeloma, suitable whole-body imaging looks for bone damage or focal marrow disease. Tissue biopsy remains central to lymphoma classification. Ask whether the scan is for diagnosis, staging, treatment response or a new symptom; the purpose changes interpretation.
MRD: a deeper response test
Measurable residual disease uses sensitive flow cytometry, PCR or sequencing to look for a small remaining cancer population. The method, specimen, timing and detection threshold must be stated. MRD-negative means disease was not detected down to that test’s limit in that sample; it does not prove that no cancer cells exist anywhere. MRD has different roles in ALL, AML, myeloma and other diseases. It does not justify stopping treatment outside a validated plan.
Reading a report with the team
- Confirm name, date, specimen and whether this is a preliminary or final report.
- Ask for the exact integrated diagnosis and any remaining uncertainty.
- Separate diagnostic markers, risk markers and drug-selection markers.
- Ask whether poor sample quality or low cell numbers limit a negative result.
- Keep the original report, not only a WhatsApp photograph of its conclusion.
Practical planning
Ask which tests will change the immediate decision and whether sample transport needs coordination with a reference laboratory. Costs and turnaround times vary by location and laboratory; prioritizing essential tests is more useful than buying every panel. An urgent clinical problem should be stabilized while confirmatory work proceeds. Explain prior transfusions, steroids and cancer treatment, which may affect interpretation.
Take-home message
A result is meaningful only with its specimen, method, sensitivity and clinical question.
Common questions
Are IHC and NGS the same?
No. IHC examines proteins in tissue; NGS reads selected genetic sequences. One cannot universally replace the other.
Can a marrow biopsy spread cancer?
A medically indicated marrow biopsy is a standard diagnostic procedure and is not considered a cause of blood cancer spreading.
Sources and further reading
Cancer Aware supports patients and families worldwide. Treatment availability, approvals and care pathways vary by country; discuss local options with your healthcare team.